Numerous health economic studies have shown that early diagnosis of Alzheimer's disease (AD) leads to significant economic and social benefits. It has been also suggested that an earlier intervention results in a higher probability of success when testing new drugs. Despite this evidence, the diagnosis of AD is still made at late stages in Europe, and even a proportion of cases remain undiagnosed. In this context, raising awareness of the importance of early diagnosis among the general population and health care professionals is of great importance. The development of new and more efficient patient engagement (PE) strategies should be a priority as well.
To read this article in full you will need to make a payment
© 2018 Published by Elsevier Inc.